1. Home
  2. CALX vs CNTA Comparison

CALX vs CNTA Comparison

Compare CALX & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Calix Inc

CALX

Calix Inc

HOLD

Current Price

$43.38

Market Cap

3.2B

ML Signal

HOLD

Logo Centessa Pharmaceuticals plc

CNTA

Centessa Pharmaceuticals plc

SELL

Current Price

$39.44

Market Cap

6.1B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CALX
CNTA
Founded
1999
2020
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
6.1B
IPO Year
2009
2021

Fundamental Metrics

Financial Performance
Metric
CALX
CNTA
Price
$43.38
$39.44
Analyst Decision
Strong Buy
Buy
Analyst Count
5
9
Target Price
$66.50
$43.17
AVG Volume (30 Days)
1.1M
3.0M
Earning Date
04-21-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
157.78
29.13
EPS
0.16
N/A
Revenue
$510,367,000.00
$15,000,000.00
Revenue This Year
$16.40
N/A
Revenue Next Year
$13.75
N/A
P/E Ratio
$258.94
N/A
Revenue Growth
11.24
N/A
52 Week Low
$40.75
$10.95
52 Week High
$71.22
$40.26

Technical Indicators

Market Signals
Indicator
CALX
CNTA
Relative Strength Index (RSI) 37.32 73.10
Support Level N/A $39.16
Resistance Level $56.30 $40.26
Average True Range (ATR) 2.04 0.19
MACD -0.54 -0.48
Stochastic Oscillator 21.50 59.18

Price Performance

Historical Comparison
CALX
CNTA

About CALX Calix Inc

Calix Inc develops, markets and sells its appliance-based platform, cloud and managed services that enable service providers of all types and sizes to innovate and transform their businesses. The company's customers utilize the real-time data and insights from Calix platforms to simplify their business and deliver experiences that excite their subscribers. The resulting growth in subscriber acquisition, loyalty and revenue creates more value for their businesses and communities. The Company's revenue is principally derived in the United States and it also has its presence in Europe, Americas excluding U.S., and Rest of World.

About CNTA Centessa Pharmaceuticals plc

Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.

Share on Social Networks: